Research ArticleClinical Studies

A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells – An Analysis for Patients with Incurable Pancreatic Cancer

YOSHIYUKI YAMAGUCHI, YOUSUKE KATATA, MAKOTO OKAWAKI, AKIRA SAWAKI and MASAHIRO YAMAMURA
Anticancer Research May 2016, 36 (5) 2307-2313;

Article Information

vol. 36 no. 5 2307-2313
PMID 
27127137
Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received March 10, 2016
  • Revision received April 11, 2016
  • Accepted April 12, 2016
  • Published online April 28, 2016.
Copyright & Usage 
Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. YOSHIYUKI YAMAGUCHI⇑,
  2. YOUSUKE KATATA,
  3. MAKOTO OKAWAKI,
  4. AKIRA SAWAKI and
  5. MASAHIRO YAMAMURA
  1. Department of Clinical Oncology, Kawasaki Medical School and Hospital, Kurashiki, Okayama, Japan
  1. Correspondence to: Yoshiyuki Yamaguchi, MD, PhD, Department of Clinical Oncology, Kawasaki Medical School and Hospital, Matsushima 577, Kurashiki, Okayama 701-0192, Japan. Tel: +81 864621111, Fax: +81 864641134, e-mail: shogo{at}med.kawasaki-m.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells – An Analysis for Patients with Incurable Pancreatic Cancer
YOSHIYUKI YAMAGUCHI, YOUSUKE KATATA, MAKOTO OKAWAKI, AKIRA SAWAKI, MASAHIRO YAMAMURA
Anticancer Research May 2016, 36 (5) 2307-2313;
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords